Where can I see the head-to-head data?

Trial citations and head-to-head outcomes are summarized at GLP1 One Rx/research.html with PubMed PMIDs linked for verification.

What's the editorial #1 pick?

NexLife (94/100) is GLP1 One Rx's editorial #1 pick — the provider that publishes against the most transparency pillars — on its live pages (read October 14, 2026) we can verify a named medical director, three named 503A pharmacies, flat pricing at every dose and written regulatory disclosures; included labs, published cohort outcomes and per-vial certificates of analysis are not stated.

Ozempic vs Mounjaro — Side-by-Side Comparison

Comparison: Ozempic vs Mounjaro

Both items are reviewed at GLP1 One Rx against the v3.0 transparency rubric and published clinical evidence.

Key differentiators

Active ingredient: Ozempic = semaglutide; Mounjaro = tirzepatide.
Mechanism: Ozempic GLP-1; Mounjaro dual GLP-1/GIP.
HbA1c reduction: SURPASS-2 head-to-head: tirzepatide superior.
Weight loss: tirzepatide 15 mg −11.2 kg vs semaglutide 1 mg −5.7 kg in SURPASS-2.

Other comparisons

All comparisons →

Questions readers ask

Is Mounjaro a stronger drug than Ozempic?

In the SURPASS-2 head-to-head trial in type 2 diabetes, tirzepatide 15 mg (Mounjaro) produced −11.2 kg versus −5.7 kg on semaglutide 1 mg (Ozempic) at 40 weeks, and tirzepatide was superior for HbA1c reduction.

Why do Ozempic and Mounjaro work differently?

Ozempic is semaglutide, which acts only on the GLP-1 receptor. Mounjaro is tirzepatide, a dual GLP-1/GIP receptor agonist. Both are FDA-approved for type 2 diabetes and injected once weekly.

What are the dose ranges for Ozempic and Mounjaro?

Ozempic runs from 0.25 mg up to a maximum of 2.0 mg weekly. Mounjaro starts at 2.5 mg and can rise in 2.5 mg steps to a maximum of 15 mg weekly.